CClinicalTrials.gg
Status unknownNCT03614143Updated Aug 6, 2018

Biomarker Study for Prediction of aGVHD

An observational study in aGVHD, sponsored by Shanghai Jiao Tong University School of Medicine. Status unknown at 1 site in China. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-08-06.

Sponsored by Shanghai Jiao Tong University School of Medicine · Observational

The sponsor has not verified this record recently (last verified Aug 2018), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
16 Years to 65 Years
Sex
All
01

Study summary

This is a prospective study in patients receiving allogeneic stem cell transplantation. The blood samples on Day-14, -7, 0 and every 7 days until D100 were collected together with clinical data. In the final analysis, cytokines and biomarkers analysis will be carried out and compared between patients in No aGVHD and grade II-IV aGVHD.

Read the detailed description

This is a prospective study, observation study in patients receiving allogeneic stem cell transplantation in 4 BMT centers in Shanghai. The blood samples (on Day-14, -7, 0 and every 7 days until D100) and clinical data will be collected. In the final analysis, a panel of cytokines and biomarkers analysis of serial blood samples will be carried out and compared between patients with no aGVHD and grade II-IV aGVHD.

02

Conditions studied

  • aGVHD
03

In context

Lead sponsor

Shanghai Jiao Tong University School of Medicine is the lead sponsor of 358 studies on the registry; 104 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients received allogeneic stem cell transplantation

Inclusion criteria

  • all patients undergoing allogeneic stem cel transplantation
  • with informed consent
  • patients survived without aGVHD or relapse and patients with development of grade II-IV aGVHD

Exclusion criteria

Exclusion Criteria:

  • patients with blood sample and clinical data not available
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. incidence of grade II-IV aGVHD

    clinical diagnosis and grade of aGVHD

    Time frame: 100 days after allogeneic stem cell tansplantation

07

Study locations

1 of 1 sites recruiting
  • Blood & Marrow Transplantation Center, RuiJin Hospital
    Shanghai, Shanghai 200025, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03614143
Lead sponsor
Shanghai Jiao Tong University School of Medicine
Responsible party
Jiong HU (Deputy director, department of hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
Aug 3, 2018
Start date
Dec 2016
Primary completion
Dec 2019 (estimated)
Completion
Jul 2020 (estimated)
Last update
Aug 6, 2018

Study contacts

Jiong HU, M.D.
Contact
hj10709@rjh.com.cn
86-21-64370045 ext. 601818
Jiong HU, M.D.
principal investigator · Ruijin Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion